公开(公告)号：US20230293680A1

公开(公告)日：2023-09-21

申请号：US18017241

申请日：2021-07-23

Applicant: Genmab B.V.

Inventor： Hilma VAN DER HORST ,  Tuna MUTIS ,  Kristin STRUMANE ,  Esther BREIJ ,  Marije OVERDIJK

IPC: A61K39/395 ,  A61K31/454 ,  A61K31/69 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/454 ,  A61K31/69 ,  A61P35/00 ,  A61K2039/507

Abstract: The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide dmg. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.

公开(公告)号：US20220411522A1

公开(公告)日：2022-12-29

申请号：US17684238

申请日：2022-03-01

Applicant: GENMAB B.V.

Inventor： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C12N15/62

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20220315661A1

公开(公告)日：2022-10-06

申请号：US17609359

申请日：2020-05-11

Applicant: GENMAB B.V.

Inventor： Ulf FORSSMANN ,  Manish GUPTA ,  Jens Thing MORTENSEN ,  Merete ELLEKILDE-PEDERSEN ,  Marije Berber OVERDIJK ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K31/573 ,  A61P35/02

Abstract: The present invention relates to a combination of two antibody molecules that bind to human DR5 antigen and their use in treating cancer. In particular, the present invention relates to dosage regimens for such anti-DR5 antibodies comprising administering to subject weekly dosages followed by biweekly dosages, or one or two priming dosage(s) followed by biweekly dosages.

公开(公告)号：US10882913B2

公开(公告)日：2021-01-05

申请号：US16451714

申请日：2019-06-25

Applicant: GENMAB B.V.

Inventor： Marije Overdijk ,  Kristin Strumane ,  Rik Rademaker ,  Esther Breij ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  C07K16/30 ,  C12N15/10 ,  A61P35/00 ,  C12N15/62 ,  A61K39/00 ,  C07K16/46 ,  A61K38/00

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.